Skip to main content

Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systol

Social Author Name
Dr. John Cush
Tweet Content
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/M6uU6i5cW4

Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barce

Social Author Name
Dr. John Cush
Tweet Content
Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

Social Author Name
Dr. John Cush
Tweet Content
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.

Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis In a dose-escalation trial in nine participants, they observ

Social Author Name
Dr. John Cush
Tweet Content
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/YDuUg44ebu

Transcranial Stimulation is Effective in Fibromyalgia A randomized, controlled clinical trial in fibromyalgia (FM) has

Social Author Name
Dr. John Cush
Tweet Content
Transcranial Stimulation is Effective in Fibromyalgia A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. https://t.co/kJk1R8ubqk

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

Social Author Name
Dr. John Cush
Tweet Content
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty

Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and

Social Author Name
Dr. John Cush
Tweet Content
Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8

2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia A collaborative EULAR/ACR expert panel has establis

Social Author Name
Dr. John Cush
Tweet Content
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/STmuNO3c2Z

⌛️ Diagnostic delay in #SpA: Better with time? 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹?

Social Author Name
Nelly ZIADE 🍀
Tweet Content
⌛️ Diagnostic delay in #SpA: Better with time? 🔹️Data from the @Official_ASAS Study 🔹️4339 patients 🔹️Delay decreased over time 🔹️Same trends across world regions & across Human Development Index categories POS0908 #EULAR2025 @RheumNow https://t.co/Y9gxQDV9KJ
Subscribe to
×